Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 8 | 13 | +0,05 % | ||
| IMMUNITYBIO | 7 | 3 | +0,55 % | ||
| MODERNA | 4 | 16 | +0,10 % | ||
| ARBUTUS BIOPHARMA | 3 | - | +0,11 % | ||
| ALNYLAM PHARMACEUTICALS | 2 | 9 | -0,06 % | ||
| ANI PHARMACEUTICALS | 2 | 5 | +0,68 % | ||
| APELLIS PHARMACEUTICALS | 2 | 4 | +0,40 % | ||
| AXSOME THERAPEUTICS | 2 | 1 | +0,23 % | ||
| MBX BIOSCIENCES | 2 | 1 | -0,78 % | ||
| LIFECORE BIOMEDICAL | 2 | - | +3,79 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:30 | Neural Therapeutics: Mit Meskalin gegen die globale Krise der psychischen Gesundheit | Small- & Micro Cap Investment | |||
| 04:18 | AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit | 309 | AFX News | WASHINGTON (dpa-AFX) - AbbVie (ABBV) and Genmab A/S (GMAB) released results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a subcutaneously administered, T-cell engaging bispecific... ► Artikel lesen | |
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 9 | GlobeNewswire (USA) | ||
| Fr | Annexon Biosciences: Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Fr | Lifecore Biomedical, Inc.: Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next? | 7 | FiercePharma | ||
| Fr | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | 3 | GlobeNewswire (USA) | ||
| Fr | NovaBridge Biosciences - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Fr | Why ImmunityBio Stock Is Skyrocketing Again Today | 25 | The Motley Fool | ||
| Fr | EILMELDUNG: Biontech startet durch - beginnt jetzt die Rallye? - das müssen Sie jetzt wissen! | Hebelschein-Spekulant | |||
| Fr | Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma | 11 | Seeking Alpha | ||
| Fr | Genmab reports positive phase 3 trial results for epcoritamab | 3 | Investing.com | ||
| Fr | Genmab: Epcoritamab zeigt in Phase-3-Studie verbessertes progressionsfreies Überleben | 8 | Investing.com Deutsch | ||
| Fr | GENMAB A/S - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| Fr | Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action | 1 | Benzinga.com | ||
| Fr | Genmab A/S: Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | 341 | Business Wire | Company Announcement Based on the topline results from the EPCORE DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps Genmab A/S (Nasdaq: GMAB) today announced... ► Artikel lesen | |
| Fr | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | 258 | Newsfile | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .